Show simple item record

dc.contributor.authorWarda, Mohamad
dc.contributor.authorMarks, Rory M.
dc.contributor.authorLinhardt, Robert J.
dc.date2002
dc.date.accessioned2022-06-27T16:19:11Z
dc.date.available2022-06-27T16:19:11Z
dc.date.issued2002-08-01
dc.identifier.citationPatents related to Dengue Virus Infection, M. Warda, R. M. Marks. R. J. Linhardt, Expert Opinions on Therapeutic Patents, Expert Opinion, 12(8), 1127-1143, 2002. .
dc.identifier.issn13543776
dc.identifier.urihttps://doi.org/10.1517/13543776.12.8.1127
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5825
dc.descriptionExpert Opinions on Therapeutic Patents, Expert Opinion, 12(8), 1127-1143
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractThis review discusses patents relevant to dengue virus infection. Dengue virus is a mosquito-transmitted flavivirus that usually causes an acute self-limited febrile illness, but may result in more severe life threatening disease. The lack of animal models that replicate features of the human disease has inhibited developing an understanding of the pathophysiology of dengue virus infection and consequently, limited investigation into potential therapeutics. However, there has been considerable progress in vaccine development and recent insights into the identity of the cells infected during the course of dengue virus infection and characterisation of cell-surface receptors used to mediate infectivity, have provided important information with therapeutic implications. There is no treatment for dengue virus infection and no vaccine is yet available, new approaches are urgently needed.
dc.description.urihttps://login.libproxy.rpi.edu/login?url=https://doi.org/10.1517/13543776.12.8.1127
dc.languageen_US
dc.language.isoENG
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofExpert Opinion on Therapeutic Patents
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titlePatents related to Dengue Virus Infection
dc.typeArticle
dcterms.accessRightshttps://login.libproxy.rpi.edu/login?url=https://doi.org/10.1517/13543776.12.8.1127
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.1517/13543776.12.8.1127
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.pages1127-1143
rpi.description.volume12


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record